Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Simufilam, taken as a pill twice a day, failed to show it was better than placebo at slowing down the progression of ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.

The International Working Group discussed diagnosing Alzheimer's disease among cognitively unimpaired individuals in a ...

Alzheimer’s is the most common type of dementia. Music therapy can improve mood and cognitive performance in Alzheimer’s ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

For more information on the foundation and more insight into what we can all do to support those suffering from these ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

I spent four crazy years writing about Cassava Sciences. Yesterday, the story ended exactly as I and many others knew it ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...